Regeneron Pharmaceuticals saw the highest growth of 1.49% in patent filings in May and 1.03% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.79% and grants by 1.03%. GlobalData’s DataBook provides a comprehensive analysis of Regeneron Pharmaceuticals‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Regeneron Pharmaceuticals has been focused on protecting inventions in United States(US) with 106 publications in Q2 2024

The United States(US) Patent Office dominates the patent filings and grants with nearly 19% filings and 17% grants. The United States(US), European Patent Office(EPO), China(CN), and Israel(IL) patent Office are among the top ten patent offices where Regeneron Pharmaceuticals is filings its patents. Among the top granted patent authorities, Regeneron Pharmaceuticals has 17% of its grants in Israel(IL), 17% in United States(US) and 11% in Australia(AU).

Amgen could be the strongest competitor for Regeneron Pharmaceuticals

In terms of grant share, Regeneron Pharmaceuticals stands first among its competitors followed by Regeneron Pharmaceuticals and Amgen.

Patents related to rare diseases and genomics lead Regeneron Pharmaceuticals's portfolio

Regeneron Pharmaceuticals has the highest number of patents in rare diseases followed by, genomics and cell & gene therapy. For rare diseases, nearly 29% of patents were filed and 33% of patents were granted in Q2 2024.

Asthma related patents lead Regeneron Pharmaceuticals portfolio followed by atopic dermatitis (atopic eczema), and skin inflammation

Regeneron Pharmaceuticals has highest number of patents in asthma followed by atopic dermatitis (atopic eczema), skin inflammation, diabetic retinopathy, and inflammation. For asthma, nearly 2% of patents were filed and 4% of patents were granted in Q2 2024.

For comprehensive analysis of Regeneron Pharmaceuticals's filings and grants, buy the databook here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.